Intussusception following rotavirus vaccine administration: Post-marketing surveillance in the National Immunization Program in Australia

Grants

Funding Acknowledgements

The APSU study was funded by the National Health and Medical Research Council (NHMRC: Enabling Grant 402784); the Department of Health and Ageing, Commonwealth Government of Australia; the Sydney Medical School, University of Sydney; CSL Limited (CSL) and GlaxoSmithKline. The PAEDS pilot study is funded by the Department of Health and Ageing, Commonwealth Government of Australia. MD holds an NHMRC Post-doctoral Fellowship (437000) and EE holds an NHMRC Practitioner Fellowship (457084). Supporting sources had no role in the study design, data collection, analysis and interpretation or writing of the article and did not control or influence the decision to submit the final manuscript for publication. CSL, Roche, Sanofi, GSK & Wyeth have occasionally provided funding for Professor Booy to attend and present at scientific meetings. Any funding received is directed to a research account at The Children's Hospital at Westmead and is not personally accepted by Professor Booy. JPB has served on data safety monitoring committees for CSL Vaccines (Australian distributor of Rotateq) for which the Murdoch Children's Research Institute (MCRI) receives payments into an educational fund. JEB served on the Clinical Events Committee for GlaxoSmithKline Human Rotavirus Vaccine Study Group. The MCRI holds a patent for a candidate investigational rotavirus vaccine, RV3-BB: for which JEB, JPB, JBC and MD are investigators but hold no financial interest.